Sigrima 420 mg Injection 14 ml is an anti-cancer medicine used in the treatment of Breast cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. The abnormal growth of cancer (malignant) cells in the breast is known as breast cancer. Sigrima 420 mg Injection 14 ml is combined with trastuzumab and docetaxel for treating patients with HER2-positive metastatic breast cancer who have not received any chemotherapy for metastatic breast cancer. This medicine is also used in combination with docetaxel and trastuzumab as a neoadjuvant treatment of breast cancer in patients with HER2-positive (human epidermal growth factor receptor 2) or as part of a complete treatment regimen for early breast cancer.

Sigrima 420 mg Injection 14 ml contains Pertuzumab as a active ingredient which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

Sigrima 420 mg Injection 14 ml may cause certain side effects such as fatigue, nausea, headache, vomiting, dizziness, hair loss, constipation, dry skin, myalgia, upper respiratory tract infections, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Sigrima 420 mg Injection 14 ml. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Sigrima 420 mg Injection 14 ml should be avoided if you are allergic to it or any other components of this medicine. Sigrima 420 mg Injection 14 ml may cause left ventricular dysfunction, anaphylaxis, or hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Sigrima 420 mg Injection 14 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. The use of Sigrima 420 mg Injection 14 ml along with the doxorubicin-containing regimen is not established. Hence, if you are on such treatment, inform your doctor before starting the treatment. Sigrima 420 mg Injection 14 ml is not recommended for use in children as the safety and efficacy are not established.

Sigrima 420 mg Injection 14 ml contains Pertuzumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis. Sigrima 420 mg Injection 14 ml is used in combination with trastuzumab and docetaxel for the treatment of breast cancer.

Sigrima 420 mg Injection 14 ml should be avoided if you are allergic to it or any other components of this medicine. Sigrima 420 mg Injection 14 ml may cause left ventricular dysfunction, anaphylaxis, or hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Sigrima 420 mg Injection 14 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. The use of Sigrima 420 mg Injection 14 ml along with the doxorubicin-containing regimen is not established. Hence, if you are on such treatment, inform your doctor before starting the treatment. Sigrima 420 mg Injection 14 ml is not recommended for use in children as the safety and efficacy are not established.